Abstract
Purpose. Boron neutron capture therapy (BNCT) is a form of radiochemotherapy that is becoming increasingly important for the treatment of malignant gliomas, malignant melanomas and other forms of cancer. Targeted delivery of boron to tumors is a critical prerequisite for successful BNCT.
Methods. Strategies that involve synthetic chemical approaches and biochemical and biophysical approaches are employed to meet this requirement. Compounds developed for targeting to tumors include borocaptate sodium (BSH) and p-boronophenylalanine (BPA) which are currently in clinical use.
Results. Boronated porphyrins, nucleosides, nucleotides and other boronated compounds show potentials as targeting molecules. Conjugation of boron compounds to macromolecules such as monoclonal antibodies, epidermal growth factor and dextran is also employed for active or passive tumor targeting.
Conclusions. Boron delivery via microparticulate carriers such as liposomes, high density lipoproteins and microcapsules is also attractive for its potential application in BNCT.
Similar content being viewed by others
REFERENCES
R. F. Barth, A. H. Soloway, R. G. Fairchild, and R. M. Brugger. Boron neutron capture therapy for cancer. Cancer 70:2995–3007 (1992).
A. H. Soloway, R. F. Barth and D. E. Carpenter. Advances in Neutron Capture Therapy, Plenum Press, New York, 1993.
B. Allen, D. Moore, and B. Harrington. Progress in Neutron Capture Therapy for Cancer, Plenum Press, New York, 1992.
J. Carlsson, S. Sjoberg, and B. S. Larsson. Present status of boron neutron capture therapy. Acta Oncol. 31(8):803–813 (1992).
R. F. Barth, A. H. Soloway, and R. G. Fairchild. Boron neutron capture therapy for cancer. Cancer Res. 50:1061–1070 (1990).
L. Dewit, R. Moss, and D. Gabel. New Developments in Neutron Capture Therapy. Eur. J. Cancer 26(8):912–914 (1990).
A. K. Asbury, R. G. Ojeann, S. L. Nielsen, and W. H. Sweet. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J. Neuropathol. Exp. Neurol. 31:278–303 (1972).
H. Hatanaka and Y. Nakagawa. Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28(5):1061–1066 (1994).
F. Flam. Boron therapy gets early test. Science 265(5180):1799 (1994).
A. H. Soloway, H. Hatanaka, and M. A. Davis. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J. Med. Chem. 10:714–717 (1967).
M. Abe, K. Kitamura, K. Amano, and H. Hatanaka. Boron-10-mercaptoundecahydrododecaborate distribution in rat brain tumors. In H. Hatanaka (Ed.), Boron Neutron Capture Therapy for Tumors, Nishimura Co. Ltd., Niigata, Japan, 1986, pp. 117–124.
H. Hatanaka, K. Amano, H. Kanemitsu, I. Ikeuchi, and T. Yoshizaki. Boron uptake by human brain tumors and quality control of boron compounds. In H. Hatanaka (ed.), Boron Neutron Capture Therapy for Tumors, Chap. 5, Nishimura Co. Ltd., Niigata, Japan, 1986, pp. 77–106.
D. Gabel. Present status and perspectives of boron neutron capture therapy. Radiother. Oncol. 30:199–205 (1994).
S. L. Kraft, P. R. Gavin, C. E. DeHann, C. W. Leathers, W. F. Bauer, D. L. Miller, and R. V. Dorn III. Borocaptate sodium—a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc. Natl. Acad. Sci. 89:11973–11977 (1992).
D. Slatkin, P. Micca, A. Forman, D. Gabel, L. Weilopolski, R. Fairchild. Boron uptake in melanoma, cerebrum and blood from Na2B12H11SH and Na4B24H22S2 administered to mice. Biochem. Pharmacol. 35(10):1771–1776 (1986).
S. C. Mehta, F. D. Boudinot, and D. R. Lu. Pharmacokinetics of sodium mercaptoundecahydrododecaborate (BSH) after intravenous injection in rats. Drug Metabol. Disp. 23(12):1368–1371 (1995).
S. C. Mehta and D. R. Lu. Interspecies pharmacokinetic scaling of BSH in mice, rats rabbits and humans. Biopharmaceutics and Drug Disposition 16:735–744 (1995).
P. G. Marshall, M. E. Miller, S. Grand, P. G. Micca, and D. N. Slatkin. Toxicities of Na2B12H11SH and Na4B24H22S2 in mice. In R. G. Fairchild, V. P. Bond, and A. D. Woodhead (eds.), Clinical Aspects of Neutron Capture Therapy, Plenum Press, New York, 1989, pp. 333–351.
D. N. Slatkin, P. L. Micca, B. H. Laster, and R. G. Fairchild. Distribution of sulfhydryl boranes in mice and rats. In R. F. Fairchild and V. P. Bond (eds.), Workshop on neutron capture therapy, Brookhaven National Laboratory-51994, Upton, 1986, pp. 173–176.
M. Miura, P. Micca, J. Heinrichs, and D. Slatkin. Synthesis and preliminary in vivo toxicity evaluation of an iodinated sulfidoborate. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 339–343.
Y. Mishima, C. Honda, M. Ichihashi, H. Obara, J. Hiratsuka, H. Fukuda, H. Karashima, T. Kobayashi, K. Kanda, and K. Yoshino. First cure of primary malignant melanoma in man by single thermal neutron capture therapy using melanoma-seeking 10B-compound. Lancet. II:388–389 (1989).
J. A. Coderre, J. A. Kalef-Ezra, R. G. Fairchild, P. L. Micca, L. E. Reinstein, and J. D. Glass. Boron neutron capture therapy of a murine melanoma. Cancer Res. 48:6313–6316 (1988).
J. A. Coderre, J. D. Glass, R. G. Fairchild, P. L. Micca, I. Fand, and D. Joel. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res. 50:138–141 (1990).
T. LaHann, C. Sills, G. Hematillake, T. Dymock, and G. Daniell. Cardiovascular toxicities associated with intravenous administration of p-Boronophenylalanine formulations. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 513–517.
T. LaHann, W. F. Bauer, and D. R. Lu. Pharmacokinetics of boronophenylalanine delivered in HP-β-cyclodextrin formulation. In R. M. Ottenbrite (ed.), Polymeric Drugs and Drug Delivery Systems, ACS Book Series 545, American Chemical Society, Washington, DC, 1994, pp. 66–78.
K. Yoshino, T. Maruyama, Y. Mori, H. Kakihana, and Y. Mishima. Capture of p-boronophenylalanine by melanin-related compounds: complex formation of p-boronophenylalanine with L-DOPA. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 249–252.
J. L. Mallesch, D. E. Moore, B. J. Allen, W. H. MacCarthy, R. Jones, and W. A. Stening. The pharmacokinetics of p-boronophenylalanine fructose in human patients with glioma and metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 28(5):1183–1188 (1994).
T. R. LaHann, D. R. Lu, G. Daniell, C. Sills, S. L. Kraft, P. R. Gavin, and W. F. Bauer. Bioavailability of intravenous formulations of p-Borophenylalanine in dog and rat. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 585–589.
I. Wyzlic, A. Soloway, R. Barth, and J. Rotaru. Synthesis and evaluation of carborane-containing amino acids for boron neutron capture therapy. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 281–284.
J. S. Hill, S. B. Kahl, A. H. Kaye, S. S. Stylli, M. S. Koo, M. F. Gonzales, N. J. Vardaxis, and C. I. Johnson. Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc. Natl. Acad. Sci. USA 89(5):1785–1789 (1992).
L. R. Huang, R. Straubinger, S. B. Kahl, M. S. Koo, J. J. Alletto, R. Mazurchuk, R. I. Chau, S. L. Thamer, and R. J. Fiel. Boronated metalloporphyrins: a novel approach to the diagnosis and treatment of cancer using contrast-enhanced MR imaging and neutron capture therapy. J. Magn. Reson. Imaging. 3(2):351–356 (1993).
R. F. Schinazi and W. H. Prusoff. Synthesis and properties of boron and silicon substituted uracil or 2′-deoxyuridine. Tetrahedr. Lett. 50:4981–4984 (1978).
R. F. Schinazi, N. M. Goudgaon, G. Fulcrand, Y. el-Kattan, Z. Lesnikowski, G. Ullas, J. Moravek, and D. C. Liotta. Cellular pharmacology and biological activity of 5-carboranyl-2′-deoxyuridine. Int. J. Radiat. Oncol. Biol. Phys. 28(5):1113–1120 (1994).
B. Spielvogel, A. Sood, W. Powell, J. Tomasz, K. Porter, and B. Shaw. Chemical and enzymatic incorporation of boron into DNA. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 389–393.
P. Lemmen, B. Werner, and B. Streicher. Ether lipids as potential boron carriers for boron neutron capture therapy: synthesis of rac-1-(9-o-carboranyl)nonyl-2-methyl-glycero-3-phosphocholine (B-Et-11-OMe). In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 297–300.
Y. Yamamoto, H. Nakamura, and H. Nemoto. Synthesis and biological properties of carboranylaziridine. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 305–308.
J. Livesey, L. Wiens, D. Wilbur, D. Hamlin, and G. Laramore. Hypoxia-selective cellular toxicity of carboranyl nitroimidazole. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 315–318.
A. Corder, A. Whittaker, D. Kelly, H. Meriaty, B. Allen, and R. Martin. Evaluation of 10B-labelled DNA ligand. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 377–381.
S. Novick, M. Quastel, S. Marcus, D. Chipman, G. Shani, R. Barth, and A. Soloway. Binding of boronated polylysine to immunoglobulin by way of glycoside moieties: Immunoreactivity and boron content. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 357–360.
R. F. Barth, D. M. Adams, A. H. Soloway, and M. Darby. In vivo distribution of boronated monoclonal antibodies and starburst dendrimers. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 351–355.
J. Capala, R. F. Barth, D. M. Adams, A. H. Soloway, and J. Carlsson. Epidermal growth factor as a potential targeting agent for delivery of 10B to malignant gliomas. In A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, Plenum Press, New York, 1993, pp. 371–375.
A. Holmberg and L. Meurling. Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy. Bioconjugate Chem. 4:570–573 (1993).
G. Gregoriadis and A. T. Florence. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential. Drugs 45(1): 15–28 (1993).
K. Shelly, D. A. Feaks, M. F. Hawthrone, P. G. Schmidt, T. A. Krisch, and W. F. Bauer. Model studies directed toward the boron neutron-capture therapy of cancer: Boron delivery to murine tumors with liposomes. Proc. Natl. Acad. Sci. USA 89:9039–43 (1992).
D. A. Feaks, K. Shelly, C. B. Knobler, and M. F. Hawthrone. Na3[B20H17NH3]: Synthesis and liposomal delivery to murine tumors. Proc. Natl. Acad. Sci. USA 91:3029–3033 (1994).
S. C. Mehta, J. C. K. Lai, and D. R. Lu. Liposomal formulations containing sodium mercaptoundecahydrododecaborate (BSH) for boron neutron capture therapy. J. Microencapsul. (In press) (1995).
H. Yanagie, T. Tomita, H. Kobayashi, Y. Fujii, T. Takahashi, K. Hasumi, H. Nariuchi, and M. Sekiguchi. Application of boronated anti-CEA immunoliposomes to tumor cell growth inhibition in in vitro boron neutron capture therapy model. Br. J. Cancer 63:522–526 (1991).
B. H. Laster, S. B. Kahl, E. A. Popenoe, D. W. Pate, and R. G. Fairchild. Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture. Cancer Res. 51:4588–4593 (1992).
Y. Akine, N. Tokita, K. Tokuuye, M. Satoh, Y. Fukumori, H. Tokumitsu, R. Kanamori, T. Kobayashi, and K. Kanda. Neutron capture therapy of murine ascites tumor with gadolinium-containing microcapsules. J. Cancer Res. Clin. Oncol. 119:71–73 (1992).
S. Mehta, J. Olson, and D. R. Lu. Brain tissue reaction following intracerebral injection of free or liposomally encapsulated BSH. Drug Delivery (In press) (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mehta, S.C., Lu, D.R. Targeted Drug Delivery for Boron Neutron Capture Therapy. Pharm Res 13, 344–351 (1996). https://doi.org/10.1023/A:1016076022267
Issue Date:
DOI: https://doi.org/10.1023/A:1016076022267